Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
Bertamini L, Oliva S, Rota-Scalabrini D, Paris L, Morè S, Corradini P, Ledda A, Gentile M, De Sabbata G, Pietrantuono G, Pascarella A, Tosi P, Curci P, Gilestro M, Capra A, Galieni P, Pisani F, Annibali O, Monaco F, Liberati AM, Palmieri S, Luppi M, Zambello R, Fazio F, Belotti A, Tacchetti P, Musto P, Boccadoro M, Gay F. Bertamini L, et al. Among authors: gilestro m. J Clin Oncol. 2022 Sep 20;40(27):3120-3131. doi: 10.1200/JCO.21.01393. Epub 2022 Jun 6. J Clin Oncol. 2022. PMID: 35666982
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies.
Caltagirone S, Ruggeri M, Aschero S, Gilestro M, Oddolo D, Gay F, Bringhen S, Musolino C, Baldini L, Musto P, Petrucci MT, Gaidano G, Passera R, Bruno B, Palumbo A, Boccadoro M, Omedè P. Caltagirone S, et al. Among authors: gilestro m. Haematologica. 2014 Oct;99(10):1611-7. doi: 10.3324/haematol.2014.103853. Epub 2014 Jul 11. Haematologica. 2014. PMID: 25015938 Free PMC article.
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.
Oliva S, Gambella M, Gilestro M, Muccio VE, Gay F, Drandi D, Ferrero S, Passera R, Pautasso C, Bernardini A, Genuardi M, Patriarca F, Saraci E, Petrucci MT, Pescosta N, Liberati AM, Caravita T, Conticello C, Rocci A, Musto P, Boccadoro M, Palumbo A, Omedè P. Oliva S, et al. Among authors: gilestro m. Oncotarget. 2017 Jan 24;8(4):5924-5935. doi: 10.18632/oncotarget.12641. Oncotarget. 2017. PMID: 27779105 Free PMC article.
Relevance of sample preparation for flow cytometry.
Muccio VE, Saraci E, Gilestro M, Oddolo D, Ruggeri M, Caltagirone S, Bruno B, Boccadoro M, Omedè P. Muccio VE, et al. Among authors: gilestro m. Int J Lab Hematol. 2018 Apr;40(2):152-158. doi: 10.1111/ijlh.12755. Epub 2017 Oct 6. Int J Lab Hematol. 2018. PMID: 28984084 Free article.
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials.
D'Agostino M, De Paoli L, Conticello C, Offidani M, Ria R, Petrucci MT, Spada S, Marcatti M, Catalano L, Gilestro M, Guglielmelli T, Baldini L, Gamberi B, Rizzi R, De Sabbata G, Di Renzo N, Patriarca F, Pezzatti S, Siniscalchi A, Ribolla R, Palumbo A, Montefusco V, Nagler A, Boccadoro M, Gay F. D'Agostino M, et al. Among authors: gilestro m. Crit Rev Oncol Hematol. 2018 Dec;132:9-16. doi: 10.1016/j.critrevonc.2018.09.008. Epub 2018 Sep 14. Crit Rev Oncol Hematol. 2018. PMID: 30447931 Free article. Review.
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Gambella M, Omedé P, Spada S, Muccio VE, Gilestro M, Saraci E, Grammatico S, Larocca A, Conticello C, Bernardini A, Gamberi B, Troia R, Liberati AM, Offidani M, Rocci A, Palumbo A, Cavo M, Sonneveld P, Boccadoro M, Oliva S. Gambella M, et al. Among authors: gilestro m. Cancer. 2019 Mar 1;125(5):750-760. doi: 10.1002/cncr.31854. Epub 2018 Dec 18. Cancer. 2019. PMID: 30561775 Free article.
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies.
Mina R, Bonello F, Petrucci MT, Liberati AM, Conticello C, Ballanti S, Musto P, Olivieri A, Benevolo G, Capra A, Gilestro M, Galieni P, Cavo M, Siniscalchi A, Palumbo A, Montefusco V, Gaidano G, Omedé P, Boccadoro M, Bringhen S. Mina R, et al. Among authors: gilestro m. Haematologica. 2021 Apr 1;106(4):1079-1085. doi: 10.3324/haematol.2019.243428. Haematologica. 2021. PMID: 32107329 Free PMC article.
Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network.
Hofste op Bruinink D, Oliva S, Rihova L, Schmitz A, Gilestro M, Te Marvelde J, Kralova R, Høholt H, Broijl A, Johnsen HE, Hajek R, Boccadoro M, Sonneveld P, Omedè P, Van der Velden VHJ. Hofste op Bruinink D, et al. Among authors: gilestro m. Haematologica. 2020 Oct 5;106(5):1496-1499. doi: 10.3324/haematol.2020.267831. Haematologica. 2020. PMID: 33054135 Free PMC article. No abstract available.
16 results